archive-fr.com » FR » C » CNG.FR

Total: 170

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CNG - PROGRAMMES
    DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN Robert Roessle Strasse 10 BERLIN DEUTSCHLAND Web site http www mdc berlin de Objective Genetic studies in model organisms and humans including human genome wide association studies have pinpointed genomic regions that contribute susceptibility to common disease However to date these data have provided limited insights into the genes molecular pathways and mechanisms underlying disease patho physiology The EU FP6 Euratools consortium has been a remarkable success that established significant research collaborations expertise and infrastructure in the EU making a major contribution to the rat focus issue of Nature Genetics Volume 40 May 2008 which featured six papers from the consortium These successes underpin the current project in which we will use state of the art and emerging large scale technologies and advanced computation in an expanded multi disciplinary approach to identify gene networks and genomic mechanisms underlying common diseases We will use the rat as a model system to identify the major functional pathways underlying human inflammatory cardiovascular and metabolic and behavioral disorders Our consortium brings together world class investigators who will use next generation sequencing technologies to generate genomic transcriptomic and epigenomic datasets To this we will add cutting edge quantitative metabonomic and proteomic datasets to give significant depth of coverage at multiple levels across pathophysiological phenotypes These datasets will be gathered annotated and integrated in relational and dynamic models that will be used in comparative analyses to understand human gene function at the level of the molecule cell tissue and organism These studies will lead to new insights into disease mechanisms through an integrative cross disciplinary approach to understanding large scale functional genomic datasets in rats and humans Participants RIJKSUNIVERSITEIT GRONINGEN GRONINGEN NEDERLAND THE UNIVERSITY OF EDINBURGH EDINBURGH UNITED KINGDOM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM PARIS

    Original URL path: http://www.cng.fr/en/projects/fp7_euratrans.html (2016-01-29)
    Open archived version from archive


  • CNG - PROGRAMMES
    Coordinator Contact Person Françoise CARRE Dr Tel 33 169081064 Fax 33 164501157 Email Contact Organisation COMMISSARIAT ENERGIE ATOMIQUE CEA RUE LEBLANC PARIS 15 FRANCE Web site http www cea fr Objective CEA is convinced that the ability of research institutes to offer attractive working conditions and career opportunities to researchers is a key factor in meeting the challenge of maintaining and boosting Europe s scientific and economic competitiveness Thus thanks to the European Commission cofunding CEA would like to develop a centralised programme dedicated to researchers transnational mobility and based on open merit competition and international peer review This programme called Eurotalents programme will aim at increasing the mobility of scientists and at offering a boost in their career thanks to the access to new research capacities Eurotalents will open world class laboratories within CEA and abroad to researchers having an excellent scientific experience and wanting to broader their career via a research project in the scientific topic s of their choice within CEA well known domains of expertise Energy environment and climate change Life sciences and biotechnology Nanosciences and nanotechnologies Science and technology of high performance computing High energy physics and physics of the universe Eurotalents will thus offer

    Original URL path: http://www.cng.fr/en/projects/fp7_eurotalents.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    3022 Fax 49 893187 3866 Email Contact Organisation HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHESFORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT GMBH Ingolstaedter Landstrasse MUNCHEN GERMANY Web site http www eva copd eu Project description The project objectives are based upon the underlying concept that COPD is characterised by emphysema and airway disease inflammation and thickening of the bronchial wall both of which lead to airway obstruction with reduced FEV These two features coexist in most patients but some patients present with either emphysema or airway disease The aim of the project is to identify markers specific to emphysema and airway disease in COPD The hypothesis of the EvA project is that the mechanisms leading to these pathologies are distinctive with regard to the type of inflammatory response and in terms of genetic predisposition The differences in pathogenesis for emphysema and inflammatory airway disease mean that the two forms of COPD are linked to different markers at the DNA RNA and protein level What methods will be used in the research By using computed tomography scans to select patients with either emphysema or airway disease the consortium will obtain material from the lung leukocytes bronchial cells and blood leukocytes and analyse elements of gene expression SNP array transcriptome Data analysis will be carried out for emphysema versus airway disease and also versus a control cohort leading to the identification of markers specifically linked to either emphysema or air way disease The markers will be elements involved in a differential pathogene sis for the different disease processes in COPD and can therefore be used for diagnostic approaches and as therapeutic targets Who will be involved The project brings together 13 partners from nine European countries and includes 10 clinical centres that identify and sample selected patients one centre for image analysis and two centres that perform

    Original URL path: http://www.cng.fr/en/projects/fp7_eva.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    INFRAQTL MADO Other Programmes France Japan Programme Franco croatian coop PHENOGENE GEN2PHEN Genotype to phenotype databases A holistic solution Coordinator Contact Person SINGER Marie Ms Tel 44 1162231799 Fax 44 1162522028 Email Contact Organisation University of Leicester University Road LEICESTER UNITED KINGDOM Web site http www gen2phen org Project description The EU is contributing 12 million to the GEN2PHEN initative involving the CNG and 16 other partners come from across Europe as well as India and South Africa The GEN2PHEN project will oversee the collection and use of data from research from around the world investigating the links between genetic variation and health The project partners will develop database components tools and technologies that will ensure that all relevant research results can be properly integrated and made available via an online portal called the GEN2PHEN Knowledge Centre Powerful search capabilities will permit researchers and doctors to access and make use of the very latest research in their field In addition to this the project will identify current needs and practices in the genotype phenotype field The ethical aspects relating to the data will also be investigated Participants HELSINGIN YLIOPISTO FINLAND PHENOSYSTEMS SA BELGIUM BIOCOMPUTING PLATFORMS LTD OY FINLAND COUNCIL OF

    Original URL path: http://www.cng.fr/en/projects/fp7_gen2phen.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    genetic variation in health and disease Coordinator Contact Person BERTERO Michela Tel 34 933160257 Fax 34 9339699832 Email Contact Organisation FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Doctor Aiguader BARCELONA SPAIN Web site http www geuvadis org Project description High throughput next generation DNA sequencing technologies allow investigators to sequence entire human genomes at an affordable price and within a short time frame The correct interpretation storage and dissemination of the large amount of produced genomics data generate major challenges Tackling these challenges requires extensive exchange of data information and knowledge between medical scientists sequencing centres bioinformatics networks and industry at the European level The GEUVADIS genetic European variation in disease Consortium aims at developing standards in quality control and assessment of sequence data models for data storage exchange and access as well as standards for the handling analysis and interpretation of sequencing data and other functional genomics datasets standards for the biological and medical interpretation of sequence data and in particular rare variants for monogenic and common disorders and finally standards for the ethics of phenotype prediction from sequence variation The partners are all involved in international sequencing initiatives 1000 GP ICGC EU and other international projects ENGAGE GEN2PHEN ENCODE TECHGENE bio banking activities BBMRI data sharing initiatives ELIXIR and the European Sequencing and Genotyping Infrastructure ESGI ensuring tight collaborations The Consortium will undertake pilot sequencing projects on selected samples from three medical fields cardiovascular neurological and metabolic using RNA RNASeq and DNA exonSeq sequencing The analysis of such samples will allow the consortium to set up standards in operating procedures and biological medical interpretation of sequence data in relation to clinical phenotypes The consortium will bring together the knowledge and resources on medical genome sequencing at a European level and allow researchers to develop and test new hypotheses on

    Original URL path: http://www.cng.fr/en/projects/fp7_geuvadis.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    model system Coordinator Contact Person LEQUARRÉ Anne Sophie Dr Tel 32 26733881 Fax 32 43664116 Email Contact Organisation UNIVERSITE DE LIEGE Place du 20 aout 7 4000 LIEGE BELGIUM Web site http www eurolupa org Project description Despite major efforts identifying susceptibility genes for common human diseases cancers cardiovascular inflammatory and neurological disorders is difficult due to the complexity of the underlying causes The dog population is composed of approximately 400 purebred breeds each one is a genetic isolate with unique characteristics resulting from selection for desired attributes or from inbreeding Dogs tend to suffer from the same range of diseases than human but the genetic complexity of these diseases within a breed is reduced as a consequence of the inbreeding and due to long range linkage disequilibrium the number of SNP markers needed to perform whole genome scans is divided by at least ten LUPA is a European effort gathering experts in genomics to take advantage of this extraordinary genetic model Veterinary clinics from 12 European countries will collect DNA samples from large cohorts of dogs suffering from a range of thoroughly defined diseases of relevance to human health The diseases are described under the different workpackage WP1 to WP5 within the left column Once the different cohorts will be built DNA samples will be sent to a centralized high throughput SNP genotyping facility The SNP genotypes will be stored in central database and made available to participating collaborating centres who will analyze the data with the support of dedicated statistical genetics platforms Following genome wide association and fine mapping the candidate genes will be followed up at the molecular level by expert animal and human genomics centers This innovative approach using the dog model will ultimately provide insights into the pathogenesis of common human diseases its primary goal

    Original URL path: http://www.cng.fr/en/projects/fp7_lupa.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    DNA tracing EPIGENOME EUMORPHIA EURAGEDIC EURNETGEN EUROAS GENOMIC BANK INFRAQTL MADO Other Programmes France Japan Programme Franco croatian coop PHENOGENE READNA REvolutionary Approaches and Devices for Nucleic Acid Analysis Coordinator Contact Person MAY Elizabeth Ms Tel 33 1 60878404 Fax 33 1 60878484 Email Contact Organisation COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES RUE LEBLANC Batiment le Ponant D PARIS 15 FRANCE Web site https www cng fr READNA Project description The READNA consortium includes projects to accelerate new breakthrough DNA sequencing technologies and methods to enhance existing analysis methods The consortium includes 16 European partners from both academia and industry and launches with a 12m grant via the European Commission s seventh Framework Programme FP7 Participants come from a diverse range of scientific disciplines The interdisciplinary nature of the consortium will allow the exploration of novel concepts of nucleic acid analysis Via the READNA project results are expected to improve many aspects of patient care including the development of new personalised medical strategies and treatments The ultimate aim will be to progress technologies enabling sequencing of an entire human genome for 1000 in less than one day Participants OXFORD NANOPORE TECHNOLOGIES LTD UNITED KINGDOM LIFE TECHNOLOGIES GMBH

    Original URL path: http://www.cng.fr/en/projects/fp7_readna.html (2016-01-29)
    Open archived version from archive

  • CNG - PROGRAMMES
    croatian coop PHENOGENE SYBARIS Finding biomarkers of anti microbial drug resistance via a systems biology analysis of fungal pathogen interactions with the human immune system Coordinator Contact Person Tom RATCLIFFE Mr Tel 44 1223492520 Fax 44 1223494468 Email Contact Organisation EUROPEAN MOLECULAR BIOLOGY LABORATORY Meyerhofstrasse HEIDELBERG DEUTSCHLAND Web site http www embl org Objective We propose a systems biology study of the specificity of response of the cell mediated immune system to fungal microorganisms in order to investigate the genetic basis of susceptibility to fungal disease and elucidate molecular mechanisms of drug resistance in fungal pathogens An integrative approach combining high throughput and traditional wet lab work with computational and bioinformatics methods will be applied to identify biomarkers of resistance to currently available treatments and to develop novel putative drug target genes and pathways in different fungi We will use Saccharomyces cerevisiae a normally non pathogenic yeast model organism Candida albicans and Aspergillus fumigatus two major recognized fungal pathogens as well as other Aspergillus spp known to be multi drug resistant and difficult to treat This project meets the criteria of the call the strategic objective of which is to confront the increasing emergence and spread of antimicrobial drug resistant pathogens in Europe by addressing a well defined class of infectious disease caused by fungal pathogens with significant morbidity and mortality in a large segment of the population and a high economic cost due to resistance The anticipated results are highly relevant to society in terms of reducing the burden of mortality and suffering in immunosuppressed patients and in terms of reducing medical costs associated with treating opportunistic fungal infections The potential economic upside for novel broad spectrum anti infectives is very large The worldwide market for antifungals is currently estimated at 4 billion US annually We tackle the issues

    Original URL path: http://www.cng.fr/en/projects/fp7_sybaris.html (2016-01-29)
    Open archived version from archive



  •